Erman Akkus/X
Nov 11, 2024, 17:49
Erman Akkus: Nivolumab-ipilimumab vs SOC for non-clear cell RCC
Erman Akkus, Medical Oncology fellow at the Ankara University, shared a post on X:
“Nivolumab-ipilimumab vs SOC for non-clear cell RCC.
SUNNIFORECAST trial, EMUC24
Met primary endpoint
12-month OS rate: 86.9% vs 76.8″
More posts featuring Erman Akkus.
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14